Microcephalin and pericentrin regulate mitotic entry via centrosome-associated Chk1

Alexandra Tibelius, Joachim Marhold, Hanswaler Zentgraf, Christoph E. Heilig, Heidemarie Neitzel, Bernard Ducommun, Anita Rauch, Anthony D. Ho, Jiri Bartek, and Alwin Krämer

1Clinical Cooperation Unit Molecular Hematology/Oncology and 2Department of Tumor Virology, German Cancer Research Center, 69120 Heidelberg, Germany
3Department of Internal Medicine V, University of Heidelberg, 69120 Heidelberg, Germany
4Institute of Human Genetics, Charité, University of Berlin, 14195 Berlin, Germany
5Laboratoire de Biologie Cellulaire et Moléculaire du Controle de la Prolifération, Centre National de la Recherche Scientifique, 31062 Toulouse, France
6Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany
7Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, 2100 Copenhagen, Denmark

Primary microcephaly, Seckel syndrome, and microcephalic osteodysplastic primordial dwarfism type II (MOPD II) are disorders exhibiting marked microcephaly, with small brain sizes reflecting reduced neuron production during fetal life. Although primary microcephaly can be caused by mutations in microcephalin (MCPH1), cells from patients with Seckel syndrome and MOPD II harbor mutations in ataxia telangiectasia and Rad3 related (ATR) or pericentrin (PCNT), leading to disturbed ATR signaling. In this study, we show that a lack of MCPH1 or PCNT results in a loss of Chk1 from centrosomes with subsequently deregulated activation of centrosomal cyclin B–Cdk1.

Introduction

Primary microcephaly is a neurodevelopmental disorder characterized by reduced brain size. The first causative gene identified encodes microcephalin (MCPH1), a protein implicated in DNA damage signaling via ataxia telangiectasia and Rad3 related (ATR; Jackson et al., 2002; Alderton et al., 2006). Accordingly, the clinical features of MCPH1 syndrome patients resemble those of Seckel syndrome, another microcephalic disorder, which can be caused by mutations in ATR or defective ATR signaling (O’Driscoll et al., 2003; Alderton et al., 2004). Recently, it has been reported that mutations in pericentrin (PCNT), resulting in the loss of PCNT from the centrosome, also cause Seckel syndrome (Griffith et al., 2008). PCNT-Seckel cells, like ATR-Seckel cells, show defects in ATR-dependent G2/M checkpoint control. This finding is further supported by the recent description of PCNT mutations in microcephalic osteodysplastic primordial dwarfism type II (MOPD II), a microcephalic disorder in which growth restriction is thought to be the consequence of mitotic failure (Rauch et al., 2008).

Mechanistically, it has been shown that MCPH1 prevents premature entry into mitosis and speculated that loss of PCNT might prevent centrosomal recruitment of the checkpoint kinase Chk1, an ATR target that controls initial activation of cyclin B–Cdk1 at the centrosome (Krämer et al., 2004; Alderton et al., 2006; Löffler et al., 2006a; Griffith et al., 2008). Activation of cyclin B–Cdk1 is the key event required for the initiation of mitosis (Nurse, 1990). Cdk1 and cyclin B accumulate at the centrosome during interphase (Bailly et al., 1989, 1992), where initial activation of the cyclin B–Cdk1 complex occurs in late prophase (Jackman et al., 2003). The accumulation of active cyclin B–Cdk1 within the nucleus shortly thereafter irreversibly commits the cell to mitosis. Therefore, regulation of cyclin B–Cdk1 activity at the centrosome is critical for controlling both cytoplasmic and nuclear mitotic events. During unperturbed cell cycles, activation of cyclin B–Cdk1 at the centrosome is mediated by Cdc25B (De Souza et al., 2000; Krämer et al., 2004), which itself is positively regulated by phosphorylation at S353 by aurora A and inhibited by Chk1-mediated S230 phosphorylation at centrosomes (Dutertre et al., 2004; Löffler et al., 2006b; Schmitt et al., 2006).

To directly address whether loss of Chk1 from centrosomes constitutes a mechanism for premature entry into mitosis in microcephaly syndromes, we examined both primary patient-derived...
cells from individuals with MCPH1<sup>427insA</sup> (MCPH1 syndrome) and PCNT<sup>3109G>T</sup> (MOPD II) mutations as well as cells treated with MCPH1- and PCNT-specific siRNAs, respectively.

**Results and discussion**

**Chk1 is lost from centrosomes in both MCPH1- and PCNT-deficient cells**

First, we analyzed whether deficiency of either MCPH1 or PCNT impacts on the abundance of Chk1 at centrosomes in human cells. Although immunofluorescence microscopy analysis with a monoclonal antibody against Chk1 revealed a pronounced centrosomal staining in both U2OS and control lymphoblastoid cells (LBCs), Chk1 levels were reduced at centrosomes in MCPH1 and PCNT siRNA–treated U2OS cells as well as in primary MCPH1<sup>427insA</sup> and PCNT<sup>3109G>T</sup> cells from patients with primary microcephaly or MOPD II, respectively (Fig. 1, A–C; and Fig. S1, A–C). This effect was independent from the cell cycle stage, as Chk1 levels were reduced to a similar extent in both cells containing a single centrosome, reflecting G0/G1 phase, and two centrosomes, reflecting S/G2 phase, respectively (Fig. S1 C). Virtually identical results were obtained when a rabbit polyclonal antibody against Chk1 was used (unpublished data).

Next, we examined the association of Chk1 with centrosomes using centrosome preparations from MCPH1<sup>427insA</sup> as well as PCNT<sup>3109G>T</sup> cells and normal LBCs. Although comparable protein amounts were loaded, the centrosome preparations from MCPH1<sup>427insA</sup> and PCNT<sup>3109G>T</sup> cells contained reduced levels of Chk1 as compared with centrosomes from control LBCs (Fig. 1 D). The loss of Chk1 from centrosomes in MCPH1- and PCNT-deficient cells was not attributable to a general shortage of cellular Chk1 in these cells, as whole cell lysates from control and MCPH1<sup>427insA</sup> or PCNT<sup>3109G>T</sup> LBCs contained almost identical Chk1 levels (Fig. 1 E). Likewise, we have described previously that Chk1 is lost from centrosomes during mitosis, although total cellular Chk1 levels are not reduced during this phase of the cell cycle (Krämer et al., 2004). On the basis of these combined in situ and biochemical analyses, we conclude that in MCPH1- and PCNT-deficient cells, Chk1 is lost from centrosomes.

**MCPH1 targets Chk1 to the centrosome**

How Chk1 is recruited to interphase centrosomes during unperturbed cell cycles remains unknown. MCPH1 has been reported to localize to centrosomes in chicken DT40 cells and to directly interact with Chk1 in vitro (Alderton et al., 2006; Jeffers et al., 2008), thereby possibly contributing to the localization of Chk1 to centrosomes. To test for this possibility, we first confirmed that endogenous human MCPH1 localizes to interphase centrosomes in control but not MCPH1<sup>427insA</sup> LBCs or MCPH1 siRNA–treated U2OS cells by immunofluorescence microscopy using an antibody raised against an N-terminal fragment (1–267 aa) of MCPH1 (CCU.M1; see Materials and methods; Fig. 2 A and Fig. S1 D). Also, in contrast to MCPH1<sup>427insA</sup> LBCs, MCPH1 was detectable in centrosome preparations from control LBCs (Fig. 2 B). Therefore, we conclude that MCPH1 indeed localizes to centrosomes.

To verify the interaction of MCPH1 with Chk1 in vivo, endogenous Chk1 was immunoprecipitated from U2OS cells transiently expressing MCPH1 fused to GFP (GFP-MCPH1), with GFP-MCPH1 being readily detectable in the immunoprecipitates (Fig. 2 C). Similarly, immunoprecipitation of GFP-MCPH1 using an anti-GFP antibody led to coimmunoprecipitation of endogenous Chk1. In contrast to the loss of centrosomal Chk1 in MCPH1-deficient cells, the centrosomal levels of MCPH1 remained virtually unchanged in U2OS cells transfected with Chk1 siRNA (Fig. 2 D), which is analogous to what has been reported for Chk1<sup>−/−</sup> DT40 cells (Jeffers et al., 2008). Thus, we conclude that MCPH1 and Chk1 interact with each other and that MCPH1 targets Chk1 to the centrosome.

**MCPH1-dependent recruitment of Chk1 to centrosomes is mediated by PCNT**

As PCNT has an established role in targeting regulatory proteins to the centrosome (Diviani et al., 2000; Chen et al., 2004), direct or indirect binding of Chk1 by PCNT might mediate the centrosomal localization of Chk1 (Griffith et al., 2008). To determine whether the loss of Chk1 from centrosomes in MCPH1-deficient cells is a consequence of a shortage of centrosomal PCNT, control and MCPH1<sup>427insA</sup> LBCs were immunostained for PCNT. In contrast to control LBCs, centrosomal PCNT signals were diminished in MCPH1<sup>427insA</sup> cells (Fig. 3, A and B; and Fig. S2 A). Immunostaining of MCPH1 siRNA– and mock siRNA–treated U2OS cells with antibodies to PCNT led to similar results. Consistently, centrosome preparations from MCPH1<sup>427insA</sup> cells contained less PCNT as compared with control LBCs (Fig. 2 B). Also, GFP-MCPH1 coimmunoprecipitated with endogenous PCNT when transiently expressed in U2OS cells (Fig. S2 B). Similarly, immunoprecipitation of GFP-MCPH1 led to coimmunoprecipitation of endogenous PCNT. Thus, MCPH1 and PCNT interact with each other, and in addition to a loss of centrosomal Chk1, PCNT is depleted from centrosomes in MCPH1-deficient cells. To the contrary, PCNT deficiency did not impact on the abundance of MCPH1 at centrosomes in PCNT<sup>3109G>T</sup> or PCNT siRNA–treated U2OS cells (Fig. 2 A). Also, the centrosomal levels of PCNT remained unchanged in both U2OS cells transfected with Chk1 siRNA and Chk1<sup>−/−</sup> DT40 cells (Fig. 3 C; Zachos et al., 2003).

To examine the relationship between PCNT and Chk1 in more detail, endogenous PCNT was immunoprecipitated from control and MCPH1<sup>427insA</sup> LBCs, respectively. Endogenous Chk1 was detectable in immunoprecipitates from both cell types (Fig. 3 D). Similarly, immunoprecipitation of endogenous Chk1 led to coimmunoprecipitation of endogenous PCNT. Thus, PCNT and Chk1 interact with each other independent from the presence of MCPH1. Collectively, we conclude that MCPH1 contributes to the centrosomal localization of PCNT and that both MCPH1 and PCNT are required to recruit Chk1 to the centrosome.

To further confirm an interaction between Chk1, MCPH1, and PCNT, we size fractionated whole cell lysates from U2OS cells transiently transfected with GFP-MCPH1 by Superose 6 gel filtration chromatography (Fig. 3 E). As additional evidence for complexity formation, all three proteins comigrated.
1151

LOSS OF CENTROSOMAL CHK1 IN MICROCEPHALY SYNDROMES

• Tibelius et al.

MCPH1 or PCNT depletion–induced loss of Chk1 from centrosomes leads to premature activation of cyclin B–Cdk1.

Centrosome-associated Chk1 prevents premature activation of cyclin B–Cdk1 and thereby mitotic entry by inhibitory phosphorylation of centrosomal Cdc25B at S230 with consecutive inhibition of P-Y15-Cdk1 dephosphorylation (Krämer et al., 2004; Schmitt et al., 2006). To determine whether down-regulation of MCPH1 or PCNT has an impact on the phosphorylation status of the centrosomal fractions of Cdc25B and Cdk1, primary

together in two fractions, which correspond to a molecular mass of >2 MD.

We next examined other components of the centrosome to establish whether they were affected by the absence of MCPH1 or PCNT (Fig. S2, C and D). Centrin, Nek2, and Cep170 were all localized normally. However, γ-tubulin was significantly reduced at interphase centrosomes in MCPH1<sup>427insA</sup> and PCNT<sup>3109G>T</sup> LBCs as compared with control LBCs, which is consistent with what has been described for mitotic PCNT- Seckel cells (Griffith et al., 2008).

**Figure 1. Chk1 levels are reduced at centrosomes in both MCPH1- and PCNT-deficient cells.** (A) Normal, MCPH1<sup>427insA</sup>, and PCNT<sup>3109G>T</sup> LBCs as well as U2OS cells transfected with luciferase- (as control [siLUC]), MCPH1-, or PCNT-specific siRNA were costained with mouse anti-Chk1 (red) and rabbit anti-γ-tubulin (green) antibodies and analyzed by confocal microscopy. Bar, 10 µm. (B) The mean percentages of cells with centrosomal colocalization of γ-tubulin and Chk1 are indicated. Error bars represent the standard deviation after combining the results of three different experiments. Statistical significance versus control (LBC) by two-tailed Student’s t test is as follows: ***, P = 9 × 10<sup>−6</sup> (MCPH1<sup>427insA</sup>); P = 0.00003 (PCNT<sup>3109G>T</sup>). (C) Quantification of pixel intensity profiles constructed from optically sectioned (z axis) fluorescence images of control, MCPH1<sup>427insA</sup>, and PCNT<sup>3109G>T</sup> LBCs. Error bars represent standard deviations from the analysis of 100 cells. Statistical significance versus control (LBC) by two-tailed Student’s t test is as follows: ***, P = 1.4 × 10<sup>−7</sup> (MCPH1<sup>427insA</sup>); P = 9.8 × 10<sup>−12</sup> (PCNT<sup>3109G>T</sup>). (D) Loss of Chk1 protein in isolated centrosome preparations. Immunoblots were performed on three sucrose gradient fractions of centrosome preparations (left) and whole cell lysates (right) as an input control from normal, MCPH1<sup>427insA</sup>, and PCNT<sup>3109G>T</sup> LBCs using antibodies against Chk1 and, for comparison, Nek2 (a centrosomal protein) and Mcm7 (a nuclear protein). For whole cell lysates, actin was included as a loading control. (E) Western blot analysis of PCNT, MCPH1, and Chk1 in whole cell lysates from control, MCPH1<sup>427insA</sup>, and PCNT<sup>3109G>T</sup> LBCs. Actin was included as a loading control. Arrowheads point to centrosomes, which are shown enlarged in insets.
well as PCNT

3109G>T
cells and normal LBCs. Although comparable protein amounts were loaded, the centrosome preparations from MCPH1

427insA
and PCNT

3109G>T
LBCs contained reduced levels of P-S230-Cdc25B or P-Y15-Cdk1 as compared with control LBCs (Fig. 4 F). Similar to immunofluorescence stainings, reduced levels of P-Y15-Cdk1 at centrosomes in MCPH1- and PCNT-deficient cells were not attributable to a general shortage of centrosomal Cdk1 in these cells, as centrosome preparations from control and MCPH1

427insA
or PCNT

3109G>T
LBCs contained almost identical Cdk1 levels (Fig. 4 F). These findings suggest that MCPH1 or PCNT depletion–induced loss of Chk1 from centrosomes leads to reduced inhibitory phosphorylation of both centrosomal Cdc25B at S230 and Cdk1 at Y15 and therefore to premature entry into mitosis. In agreement with these findings, it has been reported recently that MCPH1

427insA
and PCNT

3109G>T
LBCs were synchronized in G1/early S phase by a mimosine block and released for 8 h to reach G2 phase. Subsequently, cells were co-immunostained with antibodies to P-S230-Cdc25B or P-Y15-Cdk1 and γ-tubulin. Although centrosomes were decorated with anti-P-S230-Cdc25B in 65.7 ± 5.1% in control LBCs, only 14.0 ± 2.6% and 36.7 ± 1.5% of MCPH1

427insA
and PCNT

3109G>T
LBCs harbored centrosomes that stained positive for P-S230-Cdc25B (Fig. 4, A and B). Similarly, in contrast to control LBCs (27.3 ± 5.1%), only 5.7 ± 1.5% and 10.0 ± 1.7% of MCPH1

427insA
and PCNT

3109G>T
LBCs, respectively, harbored centrosomes with discernible P-Y15-Cdk1 decoration, despite almost all centrosomes stained positive for total Cdk1 (Fig. 4, C–E).

Next, we examined the phosphorylation status of Cdc25B and Cdk1 using centrosome preparations from MCPH1

427insA
as well as PCNT

3109G>T
cells and normal LBCs. Although comparable protein amounts were loaded, the centrosome preparations from MCPH1

427insA
and PCNT

3109G>T
cells contained reduced levels of P-S230-Cdc25B or P-Y15-Cdk1 as compared with control LBCs (Fig. 4 F). Similar to immunofluorescence stainings, reduced levels of P-Y15-Cdk1 at centrosomes in MCPH1- and PCNT-deficient cells were not attributable to a general shortage of centrosomal Cdk1 in these cells, as centrosome preparations from control and MCPH1

427insA
or PCNT

3109G>T
LBCs contained almost identical Cdk1 levels (Fig. 4 F).

These findings suggest that MCPH1 or PCNT depletion–induced loss of Chk1 from centrosomes leads to reduced inhibitory phosphorylation of both centrosomal Cdc25B at S230 and Cdk1 at Y15 and therefore to premature entry into mitosis. In agreement with these findings, it has been reported recently that

MCPH1

427insA
and PCNT

3109G>T
LBCs as well as control LBCs were synchronized in G1/early S phase by a mimosine block and released for 8 h to reach G2 phase. Subsequently, cells were co-immunostained with antibodies to P-S230-Cdc25B or P-Y15-Cdk1 and γ-tubulin. Although centrosomes were decorated with anti-P-S230-Cdc25B in 65.7 ± 5.1% in control LBCs, only 14.0 ± 2.6% and 36.7 ± 1.5% of MCPH1

427insA
and PCNT

3109G>T
LBCs harbored centrosomes that stained positive for P-S230-Cdc25B (Fig. 4, A and B). Similarly, in contrast to control LBCs (27.3 ± 5.1%), only 5.7 ± 1.5% and 10.0 ± 1.7% of MCPH1

427insA
and PCNT

3109G>T
LBCs, respectively, harbored centrosomes with discernible P-Y15-Cdk1 decoration, despite almost all centrosomes stained positive for total Cdk1 (Fig. 4, C–E).

Next, we examined the phosphorylation status of Cdc25B and Cdk1 using centrosome preparations from MCPH1

427insA
as well as PCNT

3109G>T
cells and normal LBCs. Although comparable protein amounts were loaded, the centrosome preparations from MCPH1

427insA
and PCNT

3109G>T
cells contained reduced levels of P-S230-Cdc25B or P-Y15-Cdk1 as compared with control LBCs (Fig. 4 F). Similar to immunofluorescence stainings, reduced levels of P-Y15-Cdk1 at centrosomes in MCPH1- and PCNT-deficient cells were not attributable to a general shortage of centrosomal Cdk1 in these cells, as centrosome preparations from control and MCPH1

427insA
or PCNT

3109G>T
LBCs contained almost identical Cdk1 levels (Fig. 4 F).

These findings suggest that MCPH1 or PCNT depletion–induced loss of Chk1 from centrosomes leads to reduced inhibitory phosphorylation of both centrosomal Cdc25B at S230 and Cdk1 at Y15 and therefore to premature entry into mitosis. In agreement with these findings, it has been reported recently that...
human and *Drosophila melanogaster* MCPH1-deficient cells have low levels of total P-Y15-Cdk1 in S and G2 phases, resulting in accelerated mitotic entry in MCPH1427insA LBCs and premature centrosome separation in MCPH1 mutant *Drosophila* embryos (Alderton et al., 2006; Brunk et al., 2007). To assay for the rates of cells in late G2, or mitosis, U2OS cells treated with mock-, MCPH1-, or PCNT-specific siRNAs were examined by flow cytometry measurement using P-S10–histone H3 as a mitotic marker. 72 h after MCPH1 or PCNT siRNA transfection, significantly more cells were in late G2 or mitosis (Fig. 5 A). Similar results were obtained when the cell cycle distribution of exponentially growing control, MCPH1427insA, and PCNT3109G>T LBCs was examined (Fig. 5 B and Fig. S3 A). In addition, transient transfection of MCPH1427insA LBCs with wild-type MCPH1-Flag...
Figure 4. Loss of Chk1 from centrosomes induces activation of centrosome-associated Cdc25B and Cdk1. (A, C, and D) Normal, MCPH1^{427insA}, and PCNT^{3109G>T} LBCs were synchronized in G_{1}/early S phase by a mimosine block, released for 8 h to reach G_{2} phase, and subsequently costained with rabbit anti–P-S230-Cdc25B (green) and mouse anti–γ-tubulin (red) antibodies (A), rabbit anti–P-Y15-Cdk1 (green) and mouse anti–γ-tubulin (red) antibodies (C), or mouse anti-Cdk1 (red) and rabbit anti–γ-tubulin (green) antibodies (D) and analyzed by confocal microscopy. (B) Loss of Chk1 from centrosomes induces activation of centrosome-associated Cdc25B. The mean percentages of cells with centrosomal colocalization of γ-tubulin and P-S230-Cdc25B are indicated. Statistical significance versus control (LBC) by two-tailed Student’s t test is as follows: ***, P = 0.0006 (MCPH1^{427insA}); **, P = 0.006 (PCNT^{3109G>T}). (E) Loss of Chk1 from centrosomes induces activation of centrosome-associated Cdk1. The mean percentages of cells with centrosomal colocalization of γ-tubulin and total Cdk1 (light gray bars) or P-Y15-Cdk1 (dark gray bars) are indicated. Statistical significance versus control (LBC) by two-tailed Student’s t test is as follows: *, P = 0.013 (MCPH1^{427insA}); P = 0.019 (PCNT^{3109G>T}). (F) Reduced levels of P-S230-Cdc25B and P-Y15-Cdk1 in isolated centrosome preparations from MCPH1^{427insA} and PCNT^{3109G>T} LBCs. Immunoblots were performed on three sucrose centrifugation fractions of centrosome preparations (left) and whole cell lysates (right) as an input control from control (LBC), MCPH1^{427insA}, and PCNT^{3109G>T} LBCs using antibodies against P-S230-Cdc25B, P-Y15-Cdk1, Cdk1, and, for comparison, Nek2 as a loading control and Mcm7 to exclude nuclear contamination. For whole cell lysates, antibodies to Cdc25B, Cdk1, and actin were included. Arrowheads point to centrosomes, which are shown enlarged in insets. Error bars represent the standard deviation after combining the results of three different experiments. Bars, 10 µm.
led to a significant reduction of G$_2$/mitotic cells from 1.28 ± 0.2% after mock transfection to 0.75 ± 0.1% 12 h after transfection with MCPH1-Flag (Fig. S3 B).

Time-lapse video microscopy of MCPH1 and PCNT siRNA–treated U2OS cells revealed that mitosis in these cells was prolonged as compared with U2OS cells treated with luciferase siRNA (Fig. S3, C–E). After PCNT siRNA treatment, the frequency of cells dying out of mitosis was increased as well.

**Forced immobilization of Chk1 at centrosomes leads to accumulation of MCPH1-deficient cells with premature chromosome condensation (PCC) in G$_2$ phase**

MCPH1 deficiency leads to a striking elevation in G$_2$ phase–like cells with PCC mediated by deregulated activity of nuclear condensin II (Trimborn et al., 2004, 2006; Alderton et al., 2006). If MCPH1 indeed functions to locally regulate activation of Cdk1 via centrosomal targeting of Chk1, then specific interference with centrosome-associated Chk1 should alter the impact of MCPH1 depletion on the G$_2$/M transition. To address this issue, we took advantage of a U2OS clone conditionally expressing GFP-Chk1 fused to the PCNT-AKAP450 centrosomal-targeting (PACT) domain of AKAP450, an immobile protein of the pericentriolar matrix (Gillingham and Munro, 2000; Krämer et al., 2004). In these cells, forced immobilization of wild-type Chk1 to centrosomes impairs activation of centrosome-associated Cdk1 and thereby entry into mitosis (Krämer et al., 2004). When parental U2OS cells as well as wild-type and kinase-dead versions of GFP-Chk1-PACT–expressing cells were transfected with an MCPH1-specific siRNA, 34.0 ± 5.5% of wild-type but only 14.2 ± 3.9% of kinase-dead GFP-Chk1-PACT–expressing cells and 16.2 ± 2.3% of parental U2OS cells showed a PCC phenotype 72 h after transfection (Fig. 5, C and D). These findings suggest that down-regulation of MCPH1 induces premature entry into mitosis via depletion of the centrosomal pool of Chk1. Forced immobilization of Chk1 at the centrosome prevents cell cycle progression into mitosis, leading to accumulation of cells with PCC in G$_2$ phase.
In addition to MCPH1, three other primary microcephaly genes have been identified, ASPM, CENPJ, and CDK5RAP2 (Bond et al., 2002, 2005; Bond and Woods, 2006). Their protein products have a centrosomal localization in common and are required for centrosomal function. Therefore, a unifying theme for primary microcephaly of genes functioning in the process of cell division has been proposed. However, in contrast to mutations in ATR, MCPH1, and PCNT, which can reduce both body and brain size, effects of ASPM, CENPJ, and CDK5RAP2 mutations are restricted to the brain, presumably by acting specifically on neurogenic mitosis (Bond et al., 2005). Our data provide evidence that the recruitment of Chk1 to centrosomes depends on both MCPH1 and PCNT during unperturbed cell cycle progression. In MCPH1 syndrome and MOPD II, which result from mutations in MCPH1 and PCNT, respectively, loss of Chk1 from centrosomes leads to unscheduled entry into mitosis. Consequently, loss of regulatory constraints on the initial activation of cyclin B–Cdk1 at the centrosome might be a common final path in microcephalic syndromes with reduced body size, thereby explaining for the first time why seemingly unrelated genetic defects result in a common human disease phenotype.

## Materials and methods

### Cell culture

U2OS cells were maintained in DME with 10% FCS. Control, MCPH1, and PCNT LBCs (Alderton et al., 2006; Rauch et al., 2008) were cultured in RPMI 1640 supplemented with 15% FCS. Derivatives of U2OS cells conditionally expressing wild-type or kinase-dead alleles of GFP–Chk1–PACT were generated as reported previously (Krämer et al., 2004). DT40 cells were maintained in RPMI 1640 with 10% chicken serum (Sigma-Aldrich).

### Mimosine release

Cells were incubated overnight in 0.2 mM mimosine for synchronization at G2/M. For release, cells were washed and seeded into complete medium for up to 12 h before further processing.

### Microscopy

U2OS cells grown on glass coverslips or control, MCPH1, and PCNT LBCs cytocentrifuged on glass slides at 800 rpm for 4 min using a cytocentrifuge (Cytospin 3; Shandon) were fixed in −20°C methanol/acetic acid (1:1) for 7 min. After fixation, the cells were permeabilized in 1% Triton X-100 and 0.5% NP-40 for 10 min. Immunofluorescence microscopy was performed with the combinations of antibodies specified in Figs. 1–5, S1, and S2. Fluorescence images were captured and processed using a true confocal scanner laser-scanning microscope (SP2; Leica) equipped with confocal software (2.61; Leica) and a Plan Apo 63× 1.32 NA oil immersion objective (Leica). Images were cropped and processed using Photoshop (CS3; Adobe). Matching confocal planes were analyzed in all colocalization experiments. For the quantification of centrosomal Chk1, PCNT, and γ-tubulin signals, 3D datasets were collected using a confocal laser-scanning microscope (LSM 710; Carl Zeiss, Inc.) equipped with Axiovision software (4.7.2; Carl Zeiss, Inc.) and a Plan Apo 63× 1.4 NA oil immersion objective (Carl Zeiss, Inc.). A defined volume containing the centrosome was used to measure the total intensity of the signal. Signal intensities of centrosomes from 100 interphase cells per cell line were averaged, and relative intensities in comparison with control LBCs were calculated. 3D picture reconstruction was performed using Imagel software (1.40g; provided by W. Rasband, National Institutes of Health, Bethesda, MD).

### Plasmids

MCPH1 cDNA (GenBank/EMBL/DDB accession no. NM_024596) was cloned into pEGFP-C1 (Clontech Laboratories, Inc.) containing an N-terminal GFP tag as well as into pCMV-Tag4A (Agilent Technologies) containing a C-terminal Flag tag.

### Antibodies

A phospho-specific rabbit antiserum to 5320-Cdc25B (SE4394) was raised and characterized as described previously (Schmitt et al., 2006). Mouse monoclonal antibodies to Cdk1 and GFP (B-2), rabbit antiserum to actin (I-19), Chk1 (FL-476), and HA (Y11) as well as goat and donkey antiserum to HRP were obtained from Santa Cruz Biotechnology, Inc.; a mouse monoclonal antibody to Chk1 (DCS-310) and a rabbit antiserum to γ-tubulin were obtained from Sigma-Aldrich; a mouse monoclonal antibody to γ-tubulin (TU-30) was obtained from Exbio; a mouse monoclonal antibody to Nek2 was obtained from BD; a goat antiserum to MCPH1 was obtained from R&D Systems; rabbit antiserum to PCNT, P-Y15-Cdk1, and P-S10–histone H3 were obtained from Abcam, EMD, and Millipore, respectively. Mouse monoclonal antibodies to centrin, Cep170, and lamin A were provided by J.L. Salisbury (Mayo Clinic, Rochester, MN), E.A. Nigg (University of Basel, Basel, Switzerland), and H. Herrmann-Lerdon (German Cancer Research Center, Heidelberg, Germany), respectively. Highly cross-absorbed secondary reagents Alexa Fluor 488 and 568 were obtained from Invitrogen.

### RNA interference

For siRNA-mediated ablation of Chk1, MCH1, and PCNT, U2OS cells were transfected twice (at 0 and 24 h) with the following oligonucleotide sequences: Chk1 siRNA, 5′-GGGACUCUCCUGGAAAdTdT-3′; MCPH1 siRNA, 5′-AGGAAAGUUGAGAAGAAdTdT-3′; PCNT siRNA, 5′-GCA-CUCAGUGCUGAGGAdTdT-3′; and luciferase siRNA, 5′-UAAAGCUG-AUGAAGGUAUCdTDdT-3′ by Oligofectamine reagent (Invitrogen). Cells were harvested 72 h after the first transfection.

### Isolation and analysis of human centrosomes

Centrosomes were isolated from control, MCPH1, and PCNT LBCs as described previously (Moudjou and Bornens, 1994).

### Gel filtration

Whole cell lysates were cleared by centrifugation and passed through a 0.2-µm filter. 200 µl cleared lysate was applied to a Superose 6 gel filtration column (HR 10/30; GE Healthcare) and resolved on a fast protein liquid chromatography system (GE Healthcare) according to the manufacturer’s instructions.

### Immunoprecipitation

For immunoprecipitation, cells were lysed with RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 0.2 mM PMFS, 5 mM NaF, and 1 mM Na3VO4) containing a protease inhibitor cocktail (Roche). Subsequently, the cell lysates were centrifuged at 14,000 g for 20 min. Precipitating antibodies were preincubated with protein G/A agarose beads (50% slurry; Roche) for 1 h at room temperature followed by three washes for 5 min each in RIPA buffer and overnight incubation at 4°C after adding aliquots of the cell lysate supernatant. Negative controls were generated by immunoprecipitation with an antibody to HA (Clontech Laboratories, Inc.). After three washes for 5 min each in RIPA buffer, the proteins were analyzed by immunoblotting.

### Transfection

U2OS cells were transiently transfected with 2 µg pE GFP-C1-MCPH1 using Fugene 6 (Roche) and MCPH1 LBCs with 1.5 µg pCMV-Tag4A-MCPH1 by electroporation using a MicroPorator (MP-100; Peqlab) according to the manufacturer’s instructions.

### Generation of an MCPH1-specific monoclonal antibody

A bacterially expressed and affinity-purified His-tagged MCPH1 fragment (MCPH1-1, 267′aa HIS) was used to immunize mice following a modified standard immunization protocol (Köhler and Milstein, 1975). Fusions resulted in the generation of six specific monoclonal antibodies that were subsequently subcloned. Specificity of the antibody that was eventually used for further experiments (CCU.M1), which was typed as mouse IgM, was verified by using bacterially expressed recombinant proteins as well as control and MCPH1 LBCs for Western blotting and U2OS cells for immunofluorescence staining.

### Live cell imaging

Live cell imaging of cells growing in CO2-independent Leibovitz medium (Invitrogen) on microdishes (Ibidi) was performed at 37°C in a humidified atmosphere containing 5% CO2 using the BioStation IM system (Nikon) equipped with a 63× 0.8 NA Plan Fluor objective (Nikon).
Flow cytometry

Cell cycle analysis by flow cytometry including the quantification of cells in mitosis by P-S10-histone H3 staining was performed as previously described (Rebacz et al., 2007).

Online supplemental material

Fig. S1 presents a time course of siRNA-mediated depletion of PCNT and MCPH1 as well as a characterization of a novel anti-MCPH1 antibody and illustrates that Chk1 levels are reduced at centrosomes in both MCPH1- and PCNT-deficient cells. Fig. S2 illustrates that centrosomal PCNT levels are reduced in MCPH1<sup>427insA</sup> and PCNT<sup>3109G>T</sup> LBCs irrespective of their cell cycle status, that transiently expressed GFP-PCNT1 and endogenous PCNT interact with each other in vivo, and that centrosomal levels of cyclin B1, Nek2, and Cep170, but not tubulin, are unchanged in MCPH1- and PCNT-deficient cells. Fig. S3 depicts the cell cycle distribution of MCPH1<sup>427insA</sup> and PCNT<sup>3109G>T</sup> LBCs, demonstrates that rescue of MCPH1<sup>427insA</sup> LBCs via transfection with wild-type MCPH1-Flag leads to a restored mitotic index, and outlines the mitotic fate of MCPH1- and PCNT-depleted U2OS cells. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200810159/DC1.

We thank D.A. Gillespie for providing Chk1<sup>−/−</sup> DT40 cells, J.L. Salisbury, E.a. Nigg, and H. Hermann-Irmen for providing antibodies to centrin, Cep170, and lamin A, respectively, S. Pappelefehter (Carl Zeiss, Inc., Heidelberg, Germany) for technical support, and B. Schreiter and S. Franz for excellent technical assistance.

We are grateful to the Deutsche Forschungsgemeinschaft and the European Commission (project Genome Instability in Cancer and Precancer) for financial support.

Submitted: 24 October 2008
Accepted: 29 May 2009

References

Alderton, G.K., H. Joenje, R. Varon, A.D. Borglum, P.A. Jeggo, and M. O’Driscoll. 2004. Seckel syndrome exhibits cellular features demonstrating defects in the ATR-signalling pathway. Hum. Mol. Genet. 13:3127–3138.

Alderton, G.K., L. Galbiati, E. Griffith, K.H. Surinya, H. Neitzel, A.P. Jackson, P.A. Jeggo, and M. O’Driscoll. 2006. Regulation of mitotic entry by microcephalin and its overlap with ATR signalling. Nat. Cell Biol. 8:725–733.

Bailly, E., M. Doree, P. Nurse, and M. Bornens. 1989. P34<sup>H</sup>-tubulin, is part of the nuclear and cytoplasm; part is centrosomally associated at G<sub>2</sub>/M and enters vesicles at metaphase. EMBO J. 8:3985–3995.

Bailly, E., J. Pines, T. Hunter, and M. Bornens. 1992. Cytoplasmic accumulation of cyclin B1 in human cells: association with a detergent-resistant compartment within the centrosome. J. Cell Sci. 101:529–545.

Bond, J., and C.G. Woods. 2006. Cytoskeletal genes regulating brain size. Curr. Opin. Cell Biol. 18:95–101.

Bond, J., E. Roberts, G.H. Mochida, D.J. Hampshire, S. Scott, J.M. Askham, K. Springell, M. Mahadevan, Y.J. Crow, A.F. Markham, et al. 2002. ASPM is a major determinant of cerebral cortical size. Nat. Genet. 32:316–320.

Bond, J., E. Roberts, K. Springell, S. Lizarraaga, S. Scott, J. Higgins, D.J. Hampshire, E.E. Morrison, G.F. Leal, E.O. Silva, et al. 2005. A centrosomal mechanism involving CDK5RAP2 and CENPJ controls brain size. Nat. Genet. 37:353–355.

Brunk, K., B. Vernay, E. Griffith, N.L. Reynolds, D. Strutt, P.W. Ingham, and A.P. Jackson. 2007. Microcephalin coordinates mitosis in the syncitial Drosophila embryo. J. Cell Sci. 120:3578–3588.

Chen, D., A. Purohit, H. Halilovic, S.J. Doxsey, and A.C. Newton. 2004. Centrosomal anchoring of protein kinase C beta by pericentrin controls microtubule organization, spindle function, and cytokinesis. J. Biol. Chem. 279:4829–4839.

De Souza, C.P., K.A. Ellem, and B.G. Gabrielli. 2000. Centrosomal and cytoplasmic Cdc2/cyclin B1 activation precede nuclear events in mitotic exit. Cell Res. 257:11–21.

Diviani, D., L.K. Langeberg, S.J. Doxsey, and J.D. Scott. 2000. Pericentrin anchors protein kinase A at the centrosome through a newly identified RIBinding domain. Curr. Biol. 10:417–420.

Dutertre, S., M. Cazales, M. Quaranta, C. Froment, V. Trubat, C. Dozier, G. Mirey, J.P. Houbre, N. Thieu-Fevrey, E. Schmitt, et al. 2004. Phosphorylation of CDC25B by aurora-A at the centrosome contributes to the G2-M transition. J. Cell Sci. 117:2523–2531.

Gillingham, A.K., and S. Munro. 2000. The PACT domain, a conserved centrosomal targeting motif in the coiled-coil proteins AKAP450 and pericentrin. EMBO Rep. 1:524–529.

Griffith, E., S. Walker, C.-A. Martin, P. Vagnarelli, T. Stiff, B. Vernay, N. Al Sanna, A. Saggar, B. Hamel, W.C. Earnshaw, et al. 2008. Mutations in pericentrin cause Seckel syndrome with defective ATR-dependent DNA damage signaling. Nat. Genet. 40:232–236.

Jackman, M., C. Lindon, E.A. Nigg, and J. Pines. 2003. Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat. Cell Biol. 5:143–148.

Jackson, A.P., H. Eastwood, S.M. Bell, J. Adu, C. Toomes, L.M. Carr, E. Roberts, D.J. Hampshire, Y.J. Crow, A.J. Mighell, et al. 2002. Identification of microcephalin, a protein implicated in determining the size of the human brain. Am. J. Hum. Genet. 71:136–142.

Jeffers, L.J., B.J. Coull, S.J. Stack, and C.G. Morrison. 2008. Distinct BRCt domains in Mph1p/Brit1 mediate ionizing radiation-induced focus formation and centrosomal localization. Oncogene. 27:139–144.

Köhler, G., and C. Milstein. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:495–497.

Krämer, A., N. Mailand, C. Lukas, R.G. Syljuasen, C.J. Wilkinson, E.A. Nigg, J. Bartek, and J. Lukas. 2004. Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nat. Cell Biol. 6:884–891.

Löfler, H., J. Lukas, J. Bartek, and A. Krämer. 2006a. Structure meets function – centrosomes, genome maintenance and the DNA damage response. Exp. Cell Res. 312:2633–2640.

Löfler, H., B. Rebacz, A.D. Ho, J. Lukas, J. Bartek, and A. Krämer. 2006b. Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events. Cell Cycle. 5:2543–2547.

Moudjou, M., and M. Bornens. 1994. Isolation of centrosomes from cultured animal cells. In Cell Biology: A Laboratory Handbook. J.E. Celis, editor. Academic Press, San Diego. 595–604.

Nurse, P. 1990. Universal control mechanism regulating onset of M-phase. Nature. 344:503–508.

O’Driscoll, M., V.L. Ruiz-Perez, C.G. Woods, P.A. Jeggo, and J.A. Goodship. 2003. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat. Genet. 33:497–501.

Rauch, A., C.T. Thiel, D. Schindler, U. Wick, Y.J. Crow, A.B. Eiki, A.J. van Essen, T.O. Göecke, L. Al-Gazali, K.H. Chrzanowska, et al. 2008. Mutations in the pericentrin (PCNT) gene cause primordial dwarfism. Science. 319:816–819.

Rebacz, B.T.O. Larsen, M.H. Clausen, M.H. Ronnest, H. Löfler, A.D. Ho, and A. Krämer. 2007. Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen. Cancer Res. 67:6342–6350.

Schmitt, E., R. Boutrous, C. Froment, B. Monsarrat, B. Ducommun, and C. Dozier. 2006. CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage. J. Cell Sci. 119:4249–4275.

Trimborn, M., S.M. Bell, C. Felix, Y. Rashid, H. Jafri, P.D. Griffiths, L.M. Neumann, A. Krebs, A. Reis, K. Sperling, et al. 2004. Mutations in microcephalin cause aberrant regulation of chromosome condensation. Am. J. Hum. Genet. 75:261–266.

Trimborn, M., D. Schindler, H. Neitzel, and T. Hirano. 2006. Misregulated chromosome condensation in MCPH1 primary microcephaly is mediated by condensin II. Cell Cycle. 5:322–326.

Zachos, G., M.D. Rainey, and D.A. Gillespie. 2003. Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J. 22:713–723.